2. Gene
  3. Mb - myoglobin Gene

Mb - myoglobin Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Rattus norvegicus

同用名: Glng

基因 ID: 59108 | 基因类型: protein coding

关于 Mb

功能概要

Enables oxygen binding activity. Involved in several processes, including oxygen transport; response to hydrogen peroxide; and slow-twitch skeletal muscle fiber contraction. Used to study acute kidney failure. Orthologous to human MB (myoglobin). [provided by Alliance of Genome Resources, Apr 2022]

Mb 基因产物(1)

mRNA Protein Name
NM_021588.2 NP_067599.1 myoglobin
基因本体论
  • 分子功能
  • 生物过程
分子功能 GO 注释 逻辑证据 参考文献 来源
enables oxygen binding IDA
IDA: 通过直接分析推断
16430787 RGD
enables protein binding IPI
IPI: 通过物理相互作用推断
12724130 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in oxygen transport IDA
IDA: 通过直接分析推断
17038435 RGD
involved in response to hormone IDA
IDA: 通过直接分析推断
15489001 RGD
involved in response to hydrogen peroxide IDA
IDA: 通过直接分析推断
12126758 RGD
involved in slow-twitch skeletal muscle fiber contraction IEP
IEP: 通过表达模式推断
15981298 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断
蛋白主名 其他名称

myoglobin

globin g

相关产品

Approval
生物活性分子 (4)
目录号 产品名 作用方式
纯度 是否罕见病
HY-B1029 Danazol 99.70% 是
HY-109523 Cerivastatin sodium 99.89% 否
HY-14197 Clorgyline Inhibitor 99.76% 否
HY-B1029R Danazol (Standard) / 否
Clinical Phase
生物活性分子 (11)
目录号 产品名 作用方式
纯度 Phase
HY-15518 LCL161 Inhibitor 99.91% Phase 2
HY-101567 BMS-986158 Inhibitor 99.75% Phase 2
HY-11038 Zelavespib Inhibitor 99.93% Phase 2
HY-145652 Narmafotinib Inhibitor 99.86% Phase 2
HY-11038B Zelavespib hydrochloride Inhibitor 98.80% Phase 2
HY-139577A Ninerafaxstat trihydrochloride 99.65% Phase 2
HY-E70007 Catechol O-methyltransferase, porcine liver / Phase 2
HY-164401 QBS10072S / Phase 2
HY-109071 Relmapirazin / Phase 2
HY-16309 MB-07803 Inhibitor / Phase 2
HY-112842 MBQ-167 Inhibitor 99.64% Phase 1
抗体抑制剂 (2)
目录号 产品名 作用方式
纯度 Phase
HY-P99834 Crefmirlimab Inhibitor / Phase 2
HY-P991072 MB-66 Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (366)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-N0431 Astragaloside IV Inhibitor 99.93% 否
HY-129039 Butyrolactone 3 Inhibitor 99.58% 否
HY-139665 VB124 Inhibitor 99.86% 否
HY-12810 EHop-016 Inhibitor 99.85% 否
HY-B1816 Zaprinast 99.88% 否
HY-115467 MitoBloCK-10 98.99% 否
HY-153910 AGPS-IN-1 99.74% 否
HY-16307 MB05032 Inhibitor 99.63% 否
HY-147098 dTAG-47 Degrader 99.65% 否
HY-N0448 10-Gingerol 99.34% 否
HY-119272 EF24 99.34% 否
HY-149898 HA-CD44 interaction inhibitor 1 Inhibitor 99.34% 否
HY-149897 HA-CD44 interaction inhibitor 2 Inhibitor 99.36% 否
HY-15985 CTX-0294885 Inhibitor 99.43% 否
HY-100753 STAT3-IN-1 96.28% 否
HY-13808 UNC 0631 Inhibitor 99.27% 否
HY-102069 3MB-PP1 Inhibitor 99.66% 否
HY-N1231 Sophoraflavanone G Inducer 99.72% 否
HY-139109 IR-783 Inducer 99.87% 否
HY-146751 PI3K/Akt/mTOR-IN-2 99.93% 否
HY-150233 Cys-McMMAF Inhibitor 99.45% 否
HY-117154 INH154 99.89% 否
HY-110243 CAIX Inhibitor S4 Inhibitor 99.04% 否
HY-104051 Monacolin J Inhibitor 99.22% 否
HY-115903 HIF-1α-IN-2 Inhibitor 98.48% 否
HY-159569 TfR-1-IN-1 Inhibitor 96.96% 否
HY-120373 MB710 98.81% 否
HY-Y1045 Tetrabutylammonium hydrogensulfate ≥98.0% 否
HY-13807 UNC0646 Inhibitor 99.38% 否
HY-149843 LC-MB12 99.23% 否
HY-129578 Asperphenamate ≥98.0% 否
HY-110329 ML179 Agonist 99.73% 否
HY-155309 LM-41 Inhibitor 99.82% 否
HY-155982 STAT3-IN-20 Inhibitor 99.83% 否
HY-22024 5-Hydroxyflavone 99.83% 否
HY-132305 VEGFR-3-IN-1 Inhibitor 98.76% 否
HY-108317 ABL127 Inhibitor 99.91% 否
HY-156278 FB49 Inhibitor 99.76% 否
HY-N2638 Ilexsaponin A Inhibitor 99.53% 否
HY-N8146 Bruceantinol Inhibitor 98.89% 否
HY-100353 C12-Ceramide 99.82% 否
HY-108447 BC-11 hydrobromide Inhibitor ≥99.0% 否
HY-111288 MB-07811 Agonist 99.09% 否
HY-14955 Managlinat dialanetil Inhibitor 99.67% 否
HY-164064 Anticancer agent 230 Activator 99.97% 否
HY-W143216 Azure C 65.15% 否
HY-112338 C188 98.29% 否
HY-114979 Pyoluteorin 99.90% 否
HY-119257 ABT-100 95.12% 否
HY-162352 SDU-071 Inhibitor 98.75% 否
HY-N0046 Notoginsenoside Fe 99.94% 否
HY-123081 Eburicol Inhibitor ≥98.0% 否
HY-139659 ARD-61 99.57% 否
HY-146324 PROTAC eEF2K degrader-1 Activator 98.64% 否
HY-50936S Trabectedin-d3 99.08% 否
HY-129163 HJ-PI01 Inhibitor 99.72% 否
HY-148446 eIF4A3-IN-12 Inhibitor 99.70% 否
HY-148450 eIF4A3-IN-16 Inhibitor 99.96% 否
HY-151388 hMAO-B/MB-COMT-IN-1 Inhibitor 98.04% 否
HY-156273 HDAC/JAK/BRD4-IN-1 Inhibitor / 否
HY-168929 SHP1 activator 1 99.38% 否
HY-176165 CDK9/EZH2-IN-1 Inhibitor 97.03% 否
HY-N8187 Eupalinolide O Inducer 99.82% 否
HY-114324A rel-PROTAC PARP1 degrader Degrader 98.99% 否
HY-115605 CN009543V 99.37% 否
HY-115903A HIF-1α-IN-2 hydrochloride Inhibitor 99.16% 否
HY-119331 CFM-5 Inducer 99.48% 否
HY-144699 ERRα antagonist-2 Antagonist 99.07% 否
HY-148452 eIF4A3-IN-18 Inhibitor 99.58% 否
HY-158059 DS-1-38 Inhibitor 99.60% 否
HY-15985A CTX-0294885 hydrochloride 99.60% 否
HY-162645 BPR5K230 Inhibitor / 否
HY-19513 MB-07344 Agonist 99.86% 否
HY-N0247 Saikosaponin B1 Inhibitor 99.42% 否
HY-160899A Thailanstatin A cyclohexane diamine formic 93.74% 否
HY-161456 PHGDH-IN-5 Inhibitor 98.12% 否
HY-16191 ELR510444 ≥98.0% 否
HY-101517A (S)-PI3K-IN-2 Inhibitor 99.50% 否
HY-131763 2'-O-MB-cAMP sodium 99.94% 否
HY-148443 eIF4A3-IN-9 Inhibitor 99.71% 否
HY-148444 eIF4A3-IN-10 Inhibitor 97.87% 否
HY-148445 eIF4A3-IN-11 Inhibitor 99.24% 否
HY-148447 eIF4A3-IN-13 Inhibitor 99.92% 否
HY-148448 eIF4A3-IN-14 Inhibitor 99.81% 否
HY-148449 eIF4A3-IN-15 Inhibitor / 否
HY-148451 eIF4A3-IN-17 Inhibitor 99.56% 否
HY-149636 Multi-target kinase inhibitor 2 99.82% 否
HY-155113 PROTAC Hsp90α degrader 1 Degrader 98.30% 否
HY-157797 SN-38-CM2 / 否
HY-158170 CDK7-IN-28 Inhibitor / 否
HY-159990 GPX4-IN-15 Inhibitor 98.79% 否
HY-161096 Antitumor agent-127 99.09% 否
HY-161446 USP1-IN-7 Inhibitor 99.93% 否
HY-162632 Hit 14 Inhibitor ≥99.0% 否
HY-168037 PROTAC PIN1 degrader-1 / 否
HY-168996 LA-CB1 / 否
HY-173496 ST6GAL1-IN-1 Inhibitor 99.22% 否
HY-176549 (Rac)-IBR120 Inhibitor / 否
HY-19513A MB-07344 sodium Agonist 99.07% 否
HY-N3057 Pinostrobin chalcone 99.94% 否
HY-N6990 Anhydrosecoisolariciresinol 99.94% 否
HY-P2799D Creatine Kinase MB (rCK-MB), Recombinant Human / 否
HY-W231513 MASTL/Aurora A-IN-1 Inhibitor 99.47% 否
HY-11038D Zelavespib formic Inhibitor 97.39% 否
HY-116447 Antitumor agent-159 Inducer ≥99.0% 否
HY-165421 Mps1-IN-10 Inhibitor 98.20% 否
HY-W643128 Carlina oxide Inhibitor / 否
HY-144876 RIDR-PI-103 Inducer 98.02% 否
HY-107770 Duocarmycin MB / 否
HY-115507 NMac1 / 否
HY-156403 AuM1Phe Inhibitor / 否
HY-101447 SI-2 / 否
HY-106159 SB-T-101141 Inducer / 否
HY-109523S Cerivastatin-d3 sodium / 否
HY-117093 H8-A5 Inhibitor / 否
HY-118820 MB-28767 Agonist / 否
HY-120275 CYD-2-11 / 否
HY-120421 SW116 free base / 否
HY-120800 KUNG29 Inhibitor / 否
HY-123715 Anticancer agent 255 / 否
HY-125807 IS20 / 否
HY-125958 AA9 Inhibitor / 否
HY-126005 VGSC blocker-1 Inhibitor / 否
HY-129458 Cerivastatin / 否
HY-131037 MB-0223 Inhibitor / 否
HY-131508 M&B 5124 Inhibitor / 否
HY-136289 MB-VC-MGBA / 否
HY-136747 Nek2/Hec1-IN-1 / 否
HY-139376 FGFR1 inhibitor-2 Inhibitor / 否
HY-143293 VEGFR-IN-3 / 否
HY-143468 MEK-IN-5 / 否
HY-143877 NN-390 Inhibitor / 否
HY-143903 ZL-Pin13 Inhibitor / 否
HY-144306 ERα degrader 4 / 否
HY-144638 JMX0293 / 否
HY-144642 PARP-1-IN-1 Inhibitor / 否
HY-145860 PHGDH-IN-2 / 否
HY-146037 Aurora A inhibitor 2 / 否
HY-146103 Antiproliferative agent-7 Inducer / 否
HY-146203 FAK inhibitor 6 / 否
HY-146239 EGFR/HER2/TS-IN-2 Inhibitor / 否
HY-146283 LSD1-IN-18 Inhibitor / 否
HY-146284 LSD1-IN-19 Inhibitor / 否
HY-146285 LSD1-IN-20 Inhibitor / 否
HY-146452 Anticancer agent 57 Inducer / 否
HY-146511 Anticancer agent 41 / 否
HY-146516 Anticancer agent 42 / 否
HY-146676 UR-MB108 Inhibitor / 否
HY-146783 ZINC194100678 Inhibitor / 否
HY-146786 ZMF-10 / 否
HY-147101 SK-575-NEG Inhibitor / 否
HY-147556 SK3 Channel-IN-1 Modulator / 否
HY-147670 TPB15 / 否
HY-148368 CYD-4-61 / 否
HY-149033 Kobusine derivative-2 / 否
HY-149354 Aurora kinase-IN-4 Inhibitor / 否
HY-149388 Anticancer agent 139 Inhibitor / 否
HY-149635 HIF-1α-IN-6 Inhibitor / 否
HY-149729 ICMT-IN-53 Inhibitor / 否
HY-150597 HDAC-IN-46 / 否
HY-150613 PARP1/BRD4-IN-2 / 否
HY-151390 hMAO-B/MB-COMT-IN-2 Inhibitor / 否
HY-151630 hCAIX-IN-16 Inhibitor / 否
HY-152945 Antiproliferative agent-22 Inhibitor / 否
HY-153272 Antitumor agent-93 / 否
HY-153932 NR-7h Degrader / 否
HY-155011 MB076 Inhibitor / 否
HY-155039 Antitumor agent-105 / 否
HY-155098 CNBCA Inhibitor / 否
HY-155127 Antiproliferative agent-33 Inhibitor / 否
HY-155146 Anticancer agent 146 Inducer / 否
HY-155180 FD2056 Inhibitor / 否
HY-155249 KGP591 Inhibitor / 否
HY-155350 Tubulin polymerization-IN-53 Inhibitor / 否
HY-155359 Tubulin polymerization-IN-55 Inhibitor 98.84% 否
HY-155766 PARP1-IN-14 / 否
HY-155787 SHR5428 Inhibitor / 否
HY-155965 VEGFR/PARP-IN-1 / 否
HY-155969 EGFR-IN-83 / 否
HY-156018 PI3Kα-IN-13 Inhibitor / 否
HY-156026 FAK-IN-11 Inhibitor / 否
HY-156077 anti-TNBC agent-2 Inhibitor / 否
HY-156096 HDAC3-IN-2 / 否
HY-156097 Anticancer agent 158 Inhibitor / 否
HY-156098 c-Met-IN-19 Inhibitor / 否
HY-156296 CDK9-Cyclin T1 PPI-IN-1 / 否
HY-156378 Aurora A inhibitor 3 Inhibitor / 否
HY-156402 AuM1Gly Inhibitor / 否
HY-156444 HDAC1/CDK7-IN-1 / 否
HY-156524 USP1-IN-5 Inhibitor / 否
HY-156525 USP1-IN-6 Inhibitor / 否
HY-157151 iPRMT1 Inhibitor / 否
HY-157210 CDK7-IN-26 Inhibitor / 否
HY-158387 Anticancer agent 214 Inhibitor / 否
HY-158388 Anticancer agent 215 Inhibitor / 否
HY-158389 Anticancer agent 216 Inhibitor / 否
HY-158390 Anticancer agent 217 Inhibitor / 否
HY-158439 anti-TNBC agent-7 Modulator / 否
HY-158683 KIF18A-IN-11 Inhibitor / 否
HY-159119 hDHODH-IN-15 / 否
HY-159122 CA IX-IN-2 / 否
HY-159515 PBE-AMF / 否
HY-159576 O-Me Eribulin / 否
HY-159897 PAK4-IN-5 / 否
HY-160598 Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol Inhibitor / 否
HY-160682 EGFR/HER2-IN-12 Inhibitor / 否
HY-161151 RecQ helicase-IN-1 / 否
HY-161257 CDC20-IN-1 Inducer / 否
HY-161372 PARP1/c-Met-IN-1 / 否
HY-161447 USP1-IN-8 Inhibitor / 否
HY-161517 PARP1-IN-20 Inhibitor / 否
HY-161687 Cisplatin/Dasatinib prodrug-1 Inhibitor / 否
HY-161755 Anticancer agent 232 / 否
HY-161769 HL435 / 否
HY-161770 HL389 / 否
HY-161778 ZG-126 / 否
HY-161855 VEGFR-2-IN-50 / 否
HY-161868 DLC-50 / 否
HY-161878 USP1-IN-10 Inhibitor / 否
HY-161995 FGFR1/VEGFR2-IN-2 / 否
HY-162012 HC-258 / 否
HY-162034 FAK-IN-17 Inhibitor / 否
HY-162046 Anticancer agent 178 Inducer / 否
HY-162531 KIF18A-IN-9 Inhibitor 95.03% 否
HY-162532 KIF18A-IN-10 Inhibitor / 否
HY-162575 Anticancer agent 231 / 否
HY-162614 Rogersonin E Inhibitor / 否
HY-162633 USP1-IN-9 / 否
HY-162640 LDR102 Inhibitor / 否
HY-162643 Antitumor agent-169 Inhibitor / 否
HY-162688 Anticancer agent 239 Inducer / 否
HY-162751 Anticancer agent 249 / 否
HY-162805 iNOS/TopoI-IN-1 Inhibitor / 否
HY-162826 Apoptosis inducer 27 Inducer / 否
HY-162868 c-Met/HDAC-IN-4 / 否
HY-163112 Anticancer agent 179 / 否
HY-163113 Anticancer agent 180 / 否
HY-163290 HDAC-MB Inhibitor / 否
HY-163369 HDAC6-IN-35 Inhibitor / 否
HY-163434 PRMT5/EGFR-IN-1 Inhibitor / 否
HY-163676 MI-217 / 否
HY-163709 PROTAC FAK degrader 2 Degrader / 否
HY-163760 ZM-32 Inhibitor / 否
HY-163845 YX862 Degrader / 否
HY-164320 Anticancer agent 245 / 否
HY-164349 WZ-2-033 Inhibitor / 否
HY-168093 Cetzole Inducer / 否
HY-168106 ZMF-24 / 否
HY-168154 COMT-IN-2 Inhibitor / 否
HY-168650 ROCK/HDAC-IN-1 Inhibitor / 否
HY-168720 Apoptosis inducer 32 Inducer / 否
HY-168901 Hck-IN-2 Inhibitor / 否
HY-168969 AA-BR-157 / 否
HY-169382 Melatonin-Tamoxifen Conjugate Inhibitor / 否
HY-169408 EGFR-IN-137 / 否
HY-170552 KC12 Inhibitor / 否
HY-170620 PROTAC PARP1 degrader-4 Inhibitor / 否
HY-170900 SJ44236 Degrader / 否
HY-170921 USP1-IN-11 Activator / 否
HY-170946 WR-S-462 Inhibitor / 否
HY-170947 Antitumor agent-195 Inhibitor / 否
HY-170955 HA-CD44 interaction inhibitor 3 Inhibitor / 否
HY-170965 Anticancer agent 264 Inhibitor / 否
HY-171777 Erufosine Inhibitor / 否
HY-172092 BG11 Inducer / 否
HY-172115 BGC4 / 否
HY-172159 FF2039 Inhibitor / 否
HY-172551 anti-TNBC agent-9 / 否
HY-172562 BTR2004 Inhibitor / 否
HY-172886 PI3K-IN-58 / 否
HY-172888 SPP-037 Inhibitor / 否
HY-172891 CDK9/HDAC1/HDAC3-IN-1 Inhibitor / 否
HY-172957 JNN-5 Inhibitor / 否
HY-172966 EG31 Inhibitor / 否
HY-173002 MS9024 Degrader / 否
HY-173060 ERK1/2 inhibitor 13 / 否
HY-173075 Anticancer agent 267 / 否
HY-173146 EGFR-IN-153 / 否
HY-173256 Hyp-dBET1 Degrader / 否
HY-173257 Cath-L-dBET1 Degrader / 否
HY-173296 MAGL-IN-222 Inhibitor / 否
HY-173437 CW-2 Degrader / 否
HY-173498 AR ligand 40 Antagonist / 否
HY-174160 MerTK-IN-2 / 否
HY-174211 JNK-IN-23 Inhibitor / 否
HY-174232 EGFR/CA-IX-IN-1 / 否
HY-174248 PS21M Control / 否
HY-174306 MARY1 / 否
HY-174442 PARP1-IN-40 Inhibitor / 否
HY-174457 STAT3/CAIX-IN-1 / 否
HY-174828 ATR/PARP1-IN-1 / 否
HY-174975 JY-21 Degrader / 否
HY-174992 Apoptosis inducer 39 Inducer / 否
HY-175004 PBD dimer-4 / 否
HY-175030 TNI-97 / 否
HY-175173 EGFR-IN-166 Inhibitor / 否
HY-175179 LO-3-61 Degrader / 否
HY-175269 MGB1Y Inhibitor / 否
HY-175327 LIBX-A402 Inhibitor / 否
HY-175497 ROR1-IN-4 / 否
HY-175544 anti-TNBC agent-10 / 否
HY-175638 Carbonic anhydrase-IN-35 / 否
HY-175656 MDI-117740 Inhibitor / 否
HY-175815 Apoptosis inducer 44 / 否
HY-175821 PRMT1-IN-3 / 否
HY-175846 TQFL13 Inducer / 否
HY-175874 Tubulin-IN-55 / 否
HY-176147 Apoptosis inducer 38 Inducer / 否
HY-176220 GPX4-AUTAC / 否
HY-176431 TLCD1-IN-1 Inhibitor / 否
HY-176495 SG3683 / 否
HY-176713 KWZY-11 / 否
HY-177270 CHNQD-01281 Modulator / 否
HY-D0312 Mordant Blue 13 / 否
HY-N0985 1,4,5,6-Tetrahydroxy-7,8-diprenylxanthone / 否
HY-N10965 Gambogic acid B / 否
HY-N13118 Sinopodophylline B / 否
HY-N15636 Coccinine Inhibitor / 否
HY-N2741 Vitexin B-1 Inhibitor / 否
HY-N7484 (−)-Voacangarine Inhibitor / 否
HY-N7507 Sempervirine Inhibitor / 否
HY-P10511 Pantinin-3 / 否
HY-P10760 PhAc-ALGP-Dox / 否
HY-P10790 Breast cancer targeting peptide 18–4 Inhibitor / 否
HY-P10853 Bacilotetrin C analogue Inducer / 否
HY-P10873 ST-CY14 / 否
HY-P2799H Creatine kinase-MB, Human heart / 否
HY-RS08179 MB Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS08180 MB21D2 Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-U00002A ZD-4190 hydrochloride Inhibitor / 否
HY-W072781 N-Deacetylthiocolchicine Inhibitor / 否
HY-116904 Anticancer agent 253 / 否
HY-119948 AKCI Modulator / 否
HY-131764 2'-O-MB-cGMP sodium Inhibitor / 否
HY-134395 6-MB-cAMP / 否
HY-134997 4-Oxo Docosahexaenoic Acid Agonist / 否
HY-137866 Tubulin inhibitor 9 Inhibitor / 否
HY-138210 N,O-Diacetyltyramine Inhibitor / 否
HY-139795 ZYJ-25e Inhibitor / 否
HY-139815 ZYJ-34c Inhibitor / 否
HY-14955A (Rac)-Managlinat dialanetil / 否
HY-149710 POP-3MB Inhibitor / 否
HY-149714 J6-3 Inhibitor / 否
HY-149715 R1-11 Inhibitor / 否
HY-161118 MB327 / 否
HY-161773 HL389-NHC2-PEG3-C2NH / 否
HY-164306 PROTAC PARP1 degrader-2 Degrader / 否
HY-164500 MC3629 Inhibitor / 否
HY-164521 PMMB-187 Inhibitor / 否
HY-168326 Antiproliferative agent-64 Inhibitor / 否
HY-170527 Anticancer agent 260 / 否
HY-171477 Metahexestrol Ligand / 否
HY-D2741 MB 488 NHS ester / 否
HY-D2767 MB 660R NHS Ester / 否
HY-N13163 2-Epitripdiolide / 否
HY-N15398 Chaetoglobosin E Inducer / 否
HY-P10393 ERα17p Inducer / 否
HY-RS16688 Mb Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS23123 Mb Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W010713 Meso-tetraphenylchlorin / 否
HY-W369099 HJC0152 free base / 否
HY-W667666 Anthragallol 1,2-dimethyl ether / 否
HY-W800770 MB 543 DBCO / 否
HY-W800832 MB 660R DBCO / 否
HY-16308 FBPase-IN-5 Inhibitor / 否
HY-16311 MB-7133 Inhibitor / 否
抗体抑制剂 (9)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P990806 Anti-Mouse CD20 Antibody (MB20-11) Inhibitor 95.00% 否
HY-P991316 KD014 / 否
HY-P990267 Anti-Mouse CD45RB Antibody (MB23G2) Inhibitor / 否
HY-P990622 MB-311 Inhibitor / 否
HY-P991328 MAb604.107 Inhibitor / 否
HY-P991366 IBI-397 Inhibitor / 否
HY-P991370 SBT-100 Inhibitor / 否
HY-P991426 MB-314 / 否
HY-P990823 Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Mb NCBI NCBI:4151
Canis familiaris Mb NCBI NCBI:608715
Macaca fascicularis Mb NCBI NCBI:102132612
Canis lupus familiaris Mb NCBI
Mus musculus Mb NCBI NCBI:17189
Susscrofa domestica Mb NCBI
Leporidae Mb NCBI
Macaca mulatta Mb NCBI NCBI:693269
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z